Reid to meet this afternoon with Democrats on health care reform deal

NewsGuard 100/100 Score

"Senate Democrats plan to hold a special caucus on health care reform at 5 p.m. Wednesday to discuss a tentative deal on how to change the bill's public insurance option," Roll Call reports. "A group of 10 Democrats — five centrists and five liberals — agreed Tuesday night to send a set of proposals to the Congressional Budget Office for an official score, but the details have yet to be presented to all 60 Members of the Democratic Conference. However, it's unclear how much information Senate Majority Leader Harry Reid (D-Nev.) and the 10 members of the group can share with their colleagues because the CBO has asked Reid to keep mum on the details if he wants them to provide him with a confidential score" (Pierce, 12/9).

See related stories about the announcement of the agreement last night at Kaiser Health News.

ABC News reports that President Barack Obama "threw his weight behind the Senate health care deal, hailing the 'critical progress' lawmakers made on a 'creative new framework that I believe will help pave the way for final passage and a historic achievement on behalf of the American people. I support this effort,' the president said today."

"Instead of a new government-run insurance program supported by liberal Democrats, the new Senate proposal would expand Medicare and allow people ages 55 to 64 to buy into the program, starting in 2011. It would also give people the option to purchase private insurance from a national non-profit insurance program that would be overseen by the Office of Personnel Management, which supervises the health plan that's offered to federal employees and members of Congress. There were also rumblings that a public option, supported by liberal Democrats, would kick in if the national plan failed" (Wolf and Khan, 12/9).

Reuters reports that the negotiators' decision to "replace a government-run public insurance option with a scaled-back non-profit approach, possibly resolving the bill's biggest stumbling block. ... Shares of U.S. health insurers initially rose on Wednesday on news the Senate might jettison a government-run insurance plan viewed as damaging to the industry and as a possible first step to a government takeover of the sector" (Whitesides, 12/9).

Meanwhile, CQPolitics reports that Senate debate on the health care bill has slowed over an amendment about importing prescription drugs: "The amendment offered by Byron L. Dorgan , D-N.D., and backed by John McCain, R-Ariz., would allow prescription drugs to enter the country for registered importers and individuals for personal use. ... While many Democratic senators support importing drugs, Dorgan's amendment would effectively scrap an informal agreement the White House made with the Pharmaceutical Research and Manufacturers Association (PhRMA), the brand-name drugmaker trade group. The agreement limited cuts in drug spending in the bill to ensure support from PhRMA, which has run an advertising campaign to support completion of the bill. Dorgan cited a report from the Congressional Budget Office saying drug imports would result in savings of $19.4 billion over ten years by prodding manufacturers to lower domestic prices to compete with imported drugs" (12/9).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine